Rebecca Gail Gaffney, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Latent Tuberculosis | 2 | 2021 | 225 | 0.690 |
Why?
|
| Dermatomyositis | 2 | 2019 | 224 | 0.690 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 412 | 0.540 |
Why?
|
| Antirheumatic Agents | 1 | 2018 | 1339 | 0.330 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2019 | 58 | 0.320 |
Why?
|
| Skin Diseases | 2 | 2022 | 1065 | 0.220 |
Why?
|
| Disease Progression | 1 | 2019 | 13284 | 0.210 |
Why?
|
| Quality of Life | 2 | 2019 | 12804 | 0.190 |
Why?
|
| Scleroderma, Localized | 1 | 2020 | 79 | 0.170 |
Why?
|
| Auditory Perceptual Disorders | 1 | 2019 | 36 | 0.170 |
Why?
|
| Pemphigus | 1 | 2019 | 103 | 0.170 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2022 | 2104 | 0.160 |
Why?
|
| Antibodies, Antinuclear | 1 | 2019 | 326 | 0.160 |
Why?
|
| Olivary Nucleus | 1 | 2019 | 128 | 0.160 |
Why?
|
| Mycophenolic Acid | 1 | 2020 | 343 | 0.160 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2019 | 525 | 0.130 |
Why?
|
| Speech Perception | 1 | 2019 | 489 | 0.120 |
Why?
|
| Prednisone | 1 | 2018 | 1574 | 0.120 |
Why?
|
| Calcinosis | 1 | 2022 | 1499 | 0.120 |
Why?
|
| Rheumatology | 1 | 2019 | 576 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1641 | 0.110 |
Why?
|
| Cochlea | 1 | 2019 | 828 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 2133 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 1790 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 15540 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 4149 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2019 | 7729 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 11366 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 7913 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 13989 | 0.050 |
Why?
|
| Speech Reception Threshold Test | 1 | 2019 | 17 | 0.040 |
Why?
|
| Perceptual Masking | 1 | 2019 | 94 | 0.040 |
Why?
|
| Efferent Pathways | 1 | 2019 | 167 | 0.040 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2019 | 136 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2021 | 53288 | 0.040 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2019 | 250 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 23338 | 0.040 |
Why?
|
| Male | 6 | 2020 | 350118 | 0.040 |
Why?
|
| Noise | 1 | 2019 | 279 | 0.040 |
Why?
|
| Female | 6 | 2020 | 380194 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2019 | 1216 | 0.030 |
Why?
|
| Methotrexate | 1 | 2020 | 1727 | 0.030 |
Why?
|
| Middle Aged | 4 | 2020 | 213383 | 0.030 |
Why?
|
| Humans | 8 | 2022 | 744343 | 0.030 |
Why?
|
| Adult | 4 | 2020 | 214055 | 0.030 |
Why?
|
| International Cooperation | 1 | 2019 | 1420 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1782 | 0.030 |
Why?
|
| Aged | 3 | 2020 | 163280 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2021 | 3206 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 1855 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2022 | 77449 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6756 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 12959 | 0.020 |
Why?
|
| Young Adult | 2 | 2020 | 56430 | 0.010 |
Why?
|
| Adolescent | 2 | 2020 | 85781 | 0.010 |
Why?
|
| Child | 2 | 2020 | 77709 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 41006 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 40561 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 57776 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 63114 | 0.010 |
Why?
|